CLINICAL STUDY: ATHEROSCLEROSIS
Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk
Arnold von Eckardstein, MD*,
Helmut Schulte, PhD ,
Paul Cullen, MD, FRCP* and
Gerd Assmann, MD, FRCP*
* Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Westfälische Wilhelms-Universität Münster, Münster, Germany
Institut für Arterioskleroseforschung an der Universität Münster, Münster, Germany
Manuscript received June 7, 2000;
revised manuscript received August 23, 2000,
accepted October 4, 2000.
Reprint requests and correspondence: Dr. Arnold von Eckardstein, Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Westfälische Wilhelms-Universität Münster, Albert-Schweitzer-Strasse 33, D-48129 Münster, Germany
vonecka{at}unimuenster.de
OBJECTIVES
This prospective population study was conducted to assess the role of elevated lipoprotein(a) [Lp(a)] as a coronary risk factor.
BACKGROUND
The role of elevated Lp(a) as a risk factor for coronary heart disease is controversial. In addition, little attention has been paid to the interaction of Lp(a) with other risk factors.
METHODS
A total of 788 male participants of the Prospective Cardiovascular Münster (PROCAM) study aged 35 to 65 years were followed for 10 years. Both Lp(a) and traditional cardiovascular risk factors (e.g., age, low density lipoprotein [LDL] cholesterol, high density lipoprotein [HDL] cholesterol, triglycerides, systolic blood pressure, cigarette smoking, diabetes mellitus, angina pectoris, and family history of myocardial infarction) were evaluated in 44 men who suffered from myocardial infarction, and in 744 men who survived without major coronary events or stroke. A multiple logistic function algorithm was used to estimate global cardiovascular risk by the combined effects of traditional risk factors.
RESULTS
Overall, the risk of a coronary event in men with an Lp(a)  0.2 g/liter was 2.7 times that of men with lower levels (95% confidence interval [CI]: 1.4 to 5.2). This increase in risk was most prominent in men with LDL cholesterol level 4.1 mmol/liter (relative risk [RR]: 2.6; 95% CI: 1.2 to 5.7), with HDL cholesterol  0.9 mmol/liter (RR 8.3; 95% CI: 2.0 to 35.5), with hypertension (RR 3.2; 95% CI: 1.4 to 7.2), or within the two highest global risk quintiles (relative risk: 2.7; 95% CI: 1.3 to 5.7).
CONCLUSIONS
Lp(a) increases the coronary risk, especially in men with high LDL cholesterol, low HDL cholesterol, hypertension and/or high global cardiovascular risk.
|
Abbreviations and Acronyms
| | apo | = apolipoprotein | | BMI | = body mass index | | CHD | = coronary heart disease | | HDL | = high density lipoprotein | | LDL | = low density lipoprotein | | Lp(a) | = lipoprotein(a) | | MCE | = major coronary event | | MLF | = multiple logistic function | | OR | = odds ratio | | PROCAM study | = Prospective Cardiovascular Münster study |
|
This article has been cited by other articles:
|
|
|
|
 
J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al.
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Diabetes and Vascular Disease Research,
November 1, 2008;
5(4):
319 - 335.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, and B. G. Nordestgaard
Pentanucleotide Repeat Polymorphism, Lipoprotein(a) Levels, and Risk of Ischemic Heart Disease
J. Clin. Endocrinol. Metab.,
October 1, 2008;
93(10):
3769 - 3776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Berglund and E. Anuurad
Role of Lipoprotein(a) in Cardiovascular Disease: Current and Future Perspectives
J. Am. Coll. Cardiol.,
July 8, 2008;
52(2):
132 - 134.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Kamstrup, M. Benn, A. Tybjaerg-Hansen, and B. G. Nordestgaard
Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study
Circulation,
January 15, 2008;
117(2):
176 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Rippe, T. J. Angelopoulos, and L. Zukley
The Rationale for Intervention to Reduce the Risk of Coronary Heart Disease
American Journal of Lifestyle Medicine,
January 1, 2007;
1(1):
10 - 19.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. J. Bos, C. M. A. Schipper, P. J. Koudstaal, J. C.M. Witteman, A. Hofman, and M. M.B. Breteler
High Serum C-Reactive Protein Level Is Not an Independent Predictor for Stroke: The Rotterdam Study
Circulation,
October 10, 2006;
114(15):
1591 - 1598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Assmann
Dyslipidaemia and global cardiovascular risk: clinical issues
Eur. Heart J. Suppl.,
October 1, 2006;
8(suppl_F):
F40 - F46.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Suk Danik, N. Rifai, J. E. Buring, and P. M Ridker
Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.
JAMA,
September 20, 2006;
296(11):
1363 - 1370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Shai, E. B. Rimm, S. E. Hankinson, C. Cannuscio, G. Curhan, J. E. Manson, N. Rifai, M. J. Stampfer, and J. Ma
Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier?
Eur. Heart J.,
August 2, 2005;
26(16):
1633 - 1639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Assmann
Calculating global risk: the key to intervention
Eur. Heart J. Suppl.,
July 1, 2005;
7(suppl_F):
F9 - F14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hernandez, G. Francisco, P. Chacon, and R. Simo
Lipoprotein(a) as a Risk Factor for Cardiovascular Mortality in Type 2 Diabetic Patients: A 10-year follow-up study
Diabetes Care,
April 1, 2005;
28(4):
931 - 933.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Guerra, Z. Yu, S. Marcovina, R. Peshock, J. C. Cohen, and H. H. Hobbs
Lipoprotein(a) and Apolipoprotein(a) Isoforms: No Association With Coronary Artery Calcification in The Dallas Heart Study
Circulation,
March 29, 2005;
111(12):
1471 - 1479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A Enas, A. Senthilkumar, C. Vinod, and N. Puthumana
Dyslipidaemia among Indo-Asians strategies for identification and management
The British Journal of Diabetes & Vascular Disease,
March 1, 2005;
5(2):
81 - 90.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. J. Kullo and C. M. Ballantyne
Conditional Risk Factors for Atherosclerosis
Mayo Clin. Proc.,
February 1, 2005;
80(2):
219 - 230.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. J. Kullo, K. R. Bailey, L. F. Bielak, P. F. Sheedy II, G. G. Klee, S. L. Kardia, P. A. Peyser, E. Boerwinkle, and S. T. Turner
Lack of Association Between Lipoprotein(a) and Coronary Artery Calcification in the Genetic Epidemiology Network of Arteriopathy (GENOA) Study
Mayo Clin. Proc.,
October 1, 2004;
79(10):
1258 - 1263.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Hoffmann, B.-C. Zyriax, H. Boeing, and E. Windler
A dietary pattern derived to explain biomarker variation is strongly associated with the risk of coronary artery disease
Am. J. Clinical Nutrition,
September 1, 2004;
80(3):
633 - 640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Rifai, J. Ma, F. M. Sacks, P. M. Ridker, W. J. L. Hernandez, M. J. Stampfer, and S. M. Marcovina
Apolipoprotein(a) Size and Lipoprotein(a) Concentration and Future Risk of Angina Pectoris with Evidence of Severe Coronary Atherosclerosis in Men: The Physicians' Health Study
Clin. Chem.,
August 1, 2004;
50(8):
1364 - 1371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta
Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events
Circulation,
June 29, 2004;
109(25_suppl_1):
IV-6 - IV-19.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. von Eckardstein
Is there a need for novel cardiovascular risk factors?
Nephrol. Dial. Transplant.,
April 1, 2004;
19(4):
761 - 765.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. von Eckardstein
Novel Risk Factors for Atherosclerosis
JAMA,
January 21, 2004;
291(3):
301 - 301.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Hackam and S. S. Anand
Novel Risk Factors for Atherosclerosis--Reply
JAMA,
January 21, 2004;
291(3):
301 - 302.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Marcovina, M. L. Koschinsky, J. J. Albers, and S. Skarlatos
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions
Clin. Chem.,
November 1, 2003;
49(11):
1785 - 1796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tsiara, M. Elisaf, and D. P. Mikhailidis
Influence of Smoking on Predictors of Vascular Disease
Angiology,
September 1, 2003;
54(5):
507 - 530.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. S. Ganotakis, K. Mandalaki, M. Tampakaki, N. Malliaraki, E. Mandalakis, G. Vrentzos, J. Melissas, and E. Castanas
Subclinical Hypothyroidism and Lipid Abnormalities in Older Women Attending a Vascular Disease Prevention Clinic: Effect of Thyroid Replacement Therapy
Angiology,
September 1, 2003;
54(5):
569 - 576.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. G. Hackam and S. S. Anand
Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence
JAMA,
August 20, 2003;
290(7):
932 - 940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Kreisberg and A. Oberman
Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies
J. Clin. Endocrinol. Metab.,
February 1, 2002;
87(2):
423 - 437.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. von Eckardstein, P. Cullen, and G. Assmann
Problems in the measurement of Lp(a) (millimoles per liter versus milligrams percent): Reply
J. Am. Coll. Cardiol.,
November 1, 2001;
38(5):
1584 - 1585.
[Full Text]
[PDF]
|
|
|
|
